Financiere des Professionnels Fonds d investissement inc. Purchases 13,533 Shares of DexCom, Inc. $DXCM

Financiere des Professionnels Fonds d investissement inc. lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 79.8% during the 1st quarter, HoldingsChannel reports. The fund owned 30,492 shares of the medical device company’s stock after purchasing an additional 13,533 shares during the period. Financiere des Professionnels Fonds d investissement inc.’s holdings in DexCom were worth $1,915,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of DXCM. Norges Bank bought a new position in DexCom in the fourth quarter valued at about $483,356,000. AQR Capital Management LLC boosted its stake in shares of DexCom by 597.8% during the fourth quarter. AQR Capital Management LLC now owns 3,102,789 shares of the medical device company’s stock valued at $205,932,000 after purchasing an additional 2,658,158 shares in the last quarter. Employees Provident Fund Board bought a new stake in shares of DexCom during the fourth quarter worth about $145,352,000. J. Stern & Co. LLP grew its holdings in shares of DexCom by 2,114.8% during the fourth quarter. J. Stern & Co. LLP now owns 1,601,973 shares of the medical device company’s stock worth $106,323,000 after purchasing an additional 1,529,641 shares during the last quarter. Finally, SG Americas Securities LLC increased its stake in shares of DexCom by 271.4% in the first quarter. SG Americas Securities LLC now owns 2,065,277 shares of the medical device company’s stock valued at $129,699,000 after buying an additional 1,509,219 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of DXCM opened at $76.65 on Friday. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The firm’s fifty day simple moving average is $71.16 and its two-hundred day simple moving average is $68.73. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98. The stock has a market capitalization of $29.58 billion, a P/E ratio of 32.76, a price-to-earnings-growth ratio of 1.28 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.09. The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The business’s quarterly revenue was up 15.0% on a year-over-year basis. During the same period last year, the company posted $0.32 EPS. As a group, analysts predict that DexCom, Inc. will post 2.57 EPS for the current year.

Insider Buying and Selling at DexCom

In related news, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.55, for a total transaction of $128,435.00. Following the completion of the sale, the executive vice president owned 106,353 shares of the company’s stock, valued at $8,034,969.15. This trade represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of DexCom stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $72.00, for a total value of $1,926,432.00. Following the completion of the sale, the insider owned 355,726 shares of the company’s stock, valued at approximately $25,612,272. The trade was a 7.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 71,750 shares of company stock valued at $5,163,241 over the last ninety days. Insiders own 0.28% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on DXCM shares. Evercore upgraded shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 target price on the stock in a research report on Tuesday, March 24th. Bank of America decreased their price target on shares of DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Benchmark reaffirmed a “buy” rating on shares of DexCom in a research note on Tuesday, June 23rd. Deutsche Bank Aktiengesellschaft assumed coverage on shares of DexCom in a research note on Tuesday, June 23rd. They set a “buy” rating and a $86.00 price target for the company. Finally, Wall Street Zen cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $85.36.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.